Awesome – Lifestyle
Author:
CALIWAY BIOPHARMACEUTICALS
Caliway Makes First ECO 2026 Oral Presentation on Preclinical Data of CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies, Attracting Strong Interest from International Experts and Global Pharmaceutical Companies for Its Systemic Metabolic Effects
May 19, 2026
Caliway’s Fat Reduction Drug CBL-514 Phase 2 Clinical Results Accepted by ASJ. CBL-0204’s Demonstrated Efficacy and Safety Gain Further Academic Recognition
April 13, 2026
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association’s 2026 Scientific Sessions
April 2, 2026
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at ECO 2026
March 19, 2026